Theraclion Stock price

Equities

ALTHE

FR0010120402

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris 12:35:14 2024-03-28 pm EDT 5-day change 1st Jan Change
0.38 EUR +0.80% Intraday chart for Theraclion +7.34% -2.06%
Sales 2021 1.48M 1.6M Sales 2022 1.24M 1.33M Capitalization 26.15M 28.22M
Net income 2021 -3M -3.24M Net income 2022 -4M -4.32M EV / Sales 2021 24.8 x
Net Debt 2021 6.99M 7.54M Net Debt 2022 6.52M 7.04M EV / Sales 2022 26.4 x
P/E ratio 2021
-7.93 x
P/E ratio 2022
-5.35 x
Employees 30
Yield 2021 *
-
Yield 2022
-
Free-Float 71.21%
More Fundamentals * Assessed data
Dynamic Chart
Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal Study CI
Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Inner Mongolia Furui Medical Science Co., Ltd. agreed to acquire an additional 27.78% stake in Theraclion Medical Equipment Co., Ltd. from Theraclion SA for ?1 CI
Theraclion SA announced that it has received €8.353961 million in funding from Furui Medical Science Company Luxembourg S.à r.l. CI
Theraclion Names CEO MT
Theraclion Appoints Martin Deterre as CEO CI
Theraclion SA announced that it expects to receive €7 million in funding from Furui Medical Science Company Luxembourg S.à r.l. CI
Theraclion SA announced that it expects to receive ?12.649999 million in funding from Furui Medical Science Company Luxembourg S.à r.l. CI
Global markets live: HSBC, Logitech, Uber, IBM, BP... Our Logo
Theraclion SA Auditor Raises 'Going Concern' Doubt CI
Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
France's Theraclion Gets US FDA Nod for Clinical Trial of Varicose Veins Treatment MT
Theraclion SA Announces US Food Drug Administration Approve Investigational Device Exemption Application to Initiate the Multi-Center Pivotal Study VEINRESET for the Treatment of Primary Insufficiency of Great Saphenous Veins with SONOVEIN CI
Theraclion Announces Results of First US Trial CI
University of Virginia Cancer Center to Use Theraclion's HD Technology CI
More news
1 day-0.27%
1 week-2.59%
Current month+6.52%
1 month+1.62%
3 months-4.57%
6 months-32.86%
Current year-3.09%
More quotes
1 week
0.36
Extreme 0.358
0.40
1 month
0.31
Extreme 0.308
0.40
Current year
0.31
Extreme 0.308
0.68
1 year
0.30
Extreme 0.3
0.85
3 years
0.30
Extreme 0.3
2.30
5 years
0.30
Extreme 0.3
2.76
10 years
0.30
Extreme 0.3
14.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 19-12-31
Director of Finance/CFO - -
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member - 19-02-12
Director/Board Member - 18-01-31
Chairman 67 22-01-23
More insiders
Date Price Change Volume
24-03-28 0.38 +0.80% 11 048
24-03-27 0.377 -1.31% 2,616
24-03-26 0.382 +2.69% 18,569
24-03-25 0.372 -3.38% 1,388
24-03-22 0.385 -0.26% 17,130

Real-time Euronext Paris, March 28, 2024 at 06:15 am EDT

More quotes
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of equipment (61.8%); - sale of consumables (29%); - provision of after-sales services (9.2%). Export accounts for 99.7% of net sales.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Theraclion - Euronext Paris